From £6.99 per month
ShareProphets
The one stop source for breaking news, expert analysis, and podcasts on fast-moving AIM and LSE listed shares

MINDING THE LSE’S BUSINESS

Join for as low as £6.99 per month

With ShareProphets’ membership, you receive:

• All premium articles

• Tom Winnifrith’s Bearcast

• Access to all the entire nearly 10 year archive

• ShareProphets Daily Newsletter

Advanced Oncotherapy – Worth 156p, Hardman? You’re ‘Avin’ A Giraffe

By Nigel Somerville | Wednesday 18 January 2023


Disclosure: I have no positions in any stocks mentioned, and no plans to initiate any positions within the next 72 hours. I wrote this article myself, and it expresses my own opinions. I am not receiving compensation for it (other than from ShareProphets). I have no business relationship with any company whose stock is mentioned in this article.


Paid-for investment "research" prostitute Hardman has released an update on AIM-listed Advanced Oncotherapy (AVO). This means that 1) the company is desperate for cash (no surprises there!), 2) a placing is on the way and 3) that Crispin Odey is sweating over his multiple purchases at a premium at 25p per share when the shares were trading below the 25p par price, given that they are now worth just 11.25p per share. I have much time for Odey, but he has surely called this one spectacularly wrong on multiple occasions.
You must be a registered member to read this story
ShareProphets is reader-supported journalism

Join us for free and gain access to three articles per month

Or become a member starting at £6.99 per month for all articles, the Bearcast, and our seven year archive.


Filed under:



Subscribe to our newsletter

Daily digest of our latest stories.



Search ShareProphets

Market News

Complete Coverage

Recent Comments

That Was the Week that Was

 

HAT

H&T Group – now again a Buy

Time left: 05:36:49